Clinical Trial Update: Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating dose-dense paclitaxel with pembrolizumab in platinum-resistant ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-03